135.60 0.00 (0.00%)
After hours: 5:02PM EST
|Bid||125.00 x 800|
|Ask||136.98 x 1000|
|Day's Range||132.00 - 136.50|
|52 Week Range||79.88 - 195.97|
|Beta (3Y Monthly)||3.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||201.38|
Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."
NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...
The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.
# SAGE Therapeutics Inc ### NASDAQ NMS:SAGE View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining ## Bearish sentiment Short interest | Positive Short interest is moderate for SAGE with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 11. ## Money flow ETF/Index ownership | Positive ETF activity is positive but appears to be weakening. Over the last month, growth of ETFs holding SAGE is favorable, with net inflows of $5.23 billion. This is among the highest periods of net inflows seen over the last one-year, but the rate of additional flows appears to be decreasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
The Cambridge biotech says that having two different drugs to treat postpartum could serve different sets of patients.
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.
Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.
Shares of Sage Therapeutics Inc. shot up 44% in active early-afternoon trade, after the Massachusetts-based biopharmceutical company said its treatment for postpartum depression (PPD) met the primary and secondary endpoints of a phase 3 trial. Trading volume swelled to about 3 million shares, compared with the full-day average of about 463,000 shares. The company said patients treated with SAGE-217 30 milligrams had a "statistically significant improvement" in the Hamilton Rating Scale for depression when compared with placebo, and was generally well tolerated. Separately, the company said it will provide updates on key 2019 initiatives, including drug milestones expected in the next 12-to-18 months, when it is scheduled to present last Tuesday at the J.P. Morgan Healthcare Conference. The stock has still declined 17% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has slipped 2.9% and the S&P 500 has lost 6.5%.
more than doubled in value on Monday after the company announced promising study results related to its postpartum depression treatment. Sage soared 55%, or $52.99, to as high as $150.50 in early trading on the Nasdaq Stock Exchange, up from Friday's close of $97.51. SAGE announced Monday that a Phase 3 study of its postpartum depression treatment SAGE-217 met its primary and secondary endpoints in patients with postpartum depression.
Sage Therapeutics: Results from the Phase 3 ROBIN Trial ## Sage Therapeutics’ ROBIN trial On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. The trial evaluated the safety, efficacy, and other pharmacological parameters of SAGE-217 in females with severe postpartum depression. In the ROBIN trial, SAGE-217 met the clinical trial’s primary and secondary endpoints. In the trial, patients receiving SAFE-217 demonstrated a statistically significant improvement of 17.8 points in the HAMD-17 (Hamilton Rating Scale for Depression) score. Patients receiving a placebo had a score of 13.6 points. In the trial, 45% of the patients receiving SAGE-217 achieved remission—compared to 23% of the patients receiving a placebo. To learn more about the clinical trial results, read Sage Therapeutics’ press release. The success in the clinical trial will help Sage Therapeutics with supportive data for submitting a New Drug Application to different regulatory authorities across the world to commercialize the drug. ## Stock performance On January 4, Sage Therapeutics’ stock price closed at $97.51, which represents ~9.16% growth from its previous close of $89.33 on January 3. On December 31, Sage Therapeutics’ stock price grew ~7.64% to $95.76 from its previous close of $88.99 on December 28. On January 4, the company’s stock price closed at $97.51, which is ~51% below its 52-week high of $195.97 on January 31, 2018. Sage Therapeutics hit its 52-week low of $79.88 on December 24. ## Analysts’ recommendations Among the 17 analysts tracking Sage Therapeutics in January, eight recommended a “strong buy,” eight recommended a “buy,” and one recommended a “sell.” On January 7, Sage Therapeutics had a consensus 12-month target price of $200.13, which is an ~105.24% return on investment over the next 12 months.
NEW YORK, Jan. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Sage Therapeutics, Inc. (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer, Jeff Jonas, M.D., will discuss the Company’s progress as a leading, multi-franchise CNS company in a corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “We’ve made significant progress over the last eight years and our innovative approach to discovery and development has resulted in five consecutive positive trials in mood disorders,” said Jeff Jonas, M.D., chief executive officer at Sage. As we prepare to advance our lead product candidate from development to planned commercialization, we believe we are delivering on that promise.
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / U.S. markets surged on Friday as employment data came in well above expectations. The Bureau of Labor Statistics reported 312,000 jobs were added in December, ...
In a study of 151 women suffering from the condition, those who were given oral medication developed by Cambridge-based Sage showed fewer symptoms of depression than those given a placebo.
Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study. Patients treated with SAGE-217 showed an improvement in the Hamilton Rating Scale for Depression that scores a patient on 17 different parameters, including anxiety and insomnia after two weeks of treatment, the study results showed. Postpartum depression is considered the most common medical complication linked to childbirth, which typically affects women from the third trimester of pregnancy or within four weeks after giving birth.
Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient treatment, patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p=0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,000 shares of its common stock to five new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Sage Therapeutics (SAGE) needs investors to pay close attention to the stock based on moves in the options market lately.